Literature DB >> 36067309

IRF3 inhibits nuclear translocation of NF-κB to prevent viral inflammation.

Sonam Popli1, Sukanya Chakravarty1, Shumin Fan1, Anna Glanz1, Siddhesh Aras2, Laura E Nagy2, Ganes C Sen2, Ritu Chakravarti3, Saurabh Chattopadhyay1.   

Abstract

Interferon (IFN) regulatory factor 3 (IRF3) is a transcription factor activated by phosphorylation in the cytoplasm of a virus-infected cell; by translocating to the nucleus, it induces transcription of IFN-β and other antiviral genes. We have previously reported IRF3 can also be activated, as a proapoptotic factor, by its linear polyubiquitination mediated by the RIG-I pathway. Both transcriptional and apoptotic functions of IRF3 contribute to its antiviral effect. Here, we report a nontranscriptional function of IRF3, namely, the repression of IRF3-mediated NF-κB activity (RIKA), which attenuated viral activation of NF-κB and the resultant inflammatory gene induction. In Irf3-/- mice, consequently, Sendai virus infection caused enhanced inflammation in the lungs. Mechanistically, RIKA was mediated by the direct binding of IRF3 to the p65 subunit of NF-κB in the cytoplasm, which prevented its nuclear import. A mutant IRF3 defective in both the transcriptional and the apoptotic activities was active in RIKA and inhibited virus replication. Our results demonstrated IRF3 deployed a three-pronged attack on virus replication and the accompanying inflammation.

Entities:  

Keywords:  IRF3; NF-κB; antiviral; innate immunity; viral inflammation

Mesh:

Substances:

Year:  2022        PMID: 36067309      PMCID: PMC9478676          DOI: 10.1073/pnas.2121385119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  80 in total

Review 1.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

Review 2.  Immune signaling by RIG-I-like receptors.

Authors:  Yueh-Ming Loo; Michael Gale
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

Review 3.  Interferon-Stimulated Genes: What Do They All Do?

Authors:  John W Schoggins
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

Review 4.  STING-dependent cytosolic DNA sensing pathways.

Authors:  Glen N Barber
Journal:  Trends Immunol       Date:  2013-12-02       Impact factor: 16.687

5.  Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice.

Authors:  Hideyuki Yanai; Shiho Chiba; Sho Hangai; Kohei Kometani; Asuka Inoue; Yoshitaka Kimura; Takaya Abe; Hiroshi Kiyonari; Junko Nishio; Naoko Taguchi-Atarashi; Yu Mizushima; Hideo Negishi; Rudolf Grosschedl; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-30       Impact factor: 11.205

6.  The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation.

Authors:  Louise Hilton; Kartykayan Moganeradj; Gang Zhang; Yun-Hsiang Chen; Richard E Randall; John W McCauley; Stephen Goodbourn
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 7.  Regulating IRFs in IFN Driven Disease.

Authors:  Caroline A Jefferies
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 8.  Interferon-inducible antiviral effectors.

Authors:  Anthony J Sadler; Bryan R G Williams
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

9.  A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection.

Authors:  Jonathan Maelfait; Kenny Roose; Lars Vereecke; Conor Mc Guire; Mozes Sze; Martijn J Schuijs; Monique Willart; Lorena Itati Ibañez; Hamida Hammad; Bart N Lambrecht; Rudi Beyaert; Xavier Saelens; Geert van Loo
Journal:  PLoS Pathog       Date:  2016-01-27       Impact factor: 6.823

Review 10.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.